ONC
BeOne Medicines Ltd.
Medical - Pharmaceuticals
Market Cap$33.87B
5Y Perf.+91.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ONC vs TGTX
Revenue, margins, valuation, and 5-year total return — side by side.
TGTX
TG Therapeutics, Inc.
Biotechnology
Market Cap$6.87B
5Y Perf.+130.7%
ONC vs TGTX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ONC | TGTX |
|---|---|---|
| Industry | Medical - Pharmaceuticals | Biotechnology |
| Market Cap | $33.87B | $6.87B |
| Revenue (TTM) | $5.74B | $700M |
| Net Income (TTM) | $513M | $462M |
| Gross Margin | 88.3% | 83.0% |
| Operating Margin | 12.0% | 21.3% |
| Forward P/E | 51.9x | 32.3x |
| Total Debt | $2.00B | $261M |
| Cash & Equiv. | $4.55B | $79M |
ONC vs TGTX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ONC
TGTX
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| BeOne Medicines Ltd. (ONC) | 100 | 191.5 | +91.5% |
| TG Therapeutics, In… (TGTX) | 100 | 230.7 | +130.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ONC vs TGTX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TGTX leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. BeOne Medicines Ltd. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ONC
BeOne Medicines Ltd.
The Income Pick
ONC is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.70
- 10.5% 10Y total return vs TGTX's 436.5%
- Lower volatility, beta 0.70, Low D/E 45.9%, current ratio 3.41x
Best for: income & stability and long-term compounding
TGTX
TG Therapeutics, Inc.
The Growth Play
TGTX carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 87.3%, EPS growth 17.5%, 3Y rev CAGR 5.0%
- 87.3% revenue growth vs ONC's 40.2%
- Lower P/E (32.3x vs 51.9x)
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TGTX | 87.3% revenue growth vs ONC's 40.2% |
| Value | TGTX | Lower P/E (32.3x vs 51.9x) |
| Quality / Margins | TGTX | 66.0% margin vs ONC's 8.9% |
| Stability / Safety | ONC | Beta 0.70 vs TGTX's 0.77 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ONC | +36.5% vs TGTX's +23.5% |
| Efficiency (ROA) | TGTX | 42.8% ROA vs ONC's 6.7%, ROIC 16.4% vs 18.6% |
ONC vs TGTX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
ONC vs TGTX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTGTXLAGGINGONC
ONCBeOne Medicines Ltd.
1leads
TGTXTG Therapeutics, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs ONCMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
ONC4/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TGTX5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
TGTX4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — ONC and TGTX each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ONC is the larger business by revenue, generating $5.7B annually — 8.2x TGTX's $700M. TGTX is the more profitable business, keeping 66.0% of every revenue dollar as net income compared to ONC's 8.9%. On growth, TGTX holds the edge at +69.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ONCBeOne Medicines L… | TGTXTG Therapeutics, … |
|---|---|---|
| RevenueTrailing 12 months | $5.7B | $700M |
| EBITDAEarnings before interest/tax | $948M | $150M |
| Net IncomeAfter-tax profit | $513M | $462M |
| Free Cash FlowCash after capex | $846M | -$14M |
| Gross MarginGross profit ÷ Revenue | +88.3% | +83.0% |
| Operating MarginEBIT ÷ Revenue | +12.0% | +21.3% |
| Net MarginNet income ÷ Revenue | +8.9% | +66.0% |
| FCF MarginFCF ÷ Revenue | +14.7% | -2.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +35.5% | +69.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +2547.0% | +2.9% |
Evenly matched — ONC and TGTX each lead in 3 of 6 comparable metrics.
Valuation Metrics
ONC leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
At 9.6x trailing earnings, ONC trades at a 38% valuation discount to TGTX's 15.5x P/E. On an enterprise value basis, ONC's 53.2x EV/EBITDA is more attractive than TGTX's 57.1x.
| Metric | ONCBeOne Medicines L… | TGTXTG Therapeutics, … |
|---|---|---|
| Market CapShares × price | $33.9B | $6.9B |
| Enterprise ValueMkt cap + debt − cash | $31.3B | $7.1B |
| Trailing P/EPrice ÷ TTM EPS | 9.64x | 15.53x |
| Forward P/EPrice ÷ next-FY EPS est. | 51.91x | 32.25x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 53.20x | 57.07x |
| Price / SalesMarket cap ÷ Revenue | 6.34x | 11.15x |
| Price / BookPrice ÷ Book value/share | 8.25x | 10.72x |
| Price / FCFMarket cap ÷ FCF | 35.97x | — |
ONC leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
TGTX leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
TGTX delivers a 87.4% return on equity — every $100 of shareholder capital generates $87 in annual profit, vs $12 for ONC. TGTX carries lower financial leverage with a 0.40x debt-to-equity ratio, signaling a more conservative balance sheet compared to ONC's 0.46x. On the Piotroski fundamental quality scale (0–9), ONC scores 7/9 vs TGTX's 4/9, reflecting strong financial health.
| Metric | ONCBeOne Medicines L… | TGTXTG Therapeutics, … |
|---|---|---|
| ROE (TTM)Return on equity | +12.1% | +87.4% |
| ROA (TTM)Return on assets | +6.7% | +42.8% |
| ROICReturn on invested capital | +18.6% | +16.4% |
| ROCEReturn on capital employed | +8.9% | +17.7% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 4 |
| Debt / EquityFinancial leverage | 0.46x | 0.40x |
| Net DebtTotal debt minus cash | -$2.5B | $182M |
| Cash & Equiv.Liquid assets | $4.5B | $79M |
| Total DebtShort + long-term debt | $2.0B | $261M |
| Interest CoverageEBIT ÷ Interest expense | 17.46x | 5.67x |
TGTX leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
TGTX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TGTX five years ago would be worth $10,703 today (with dividends reinvested), compared to $10,161 for ONC. Over the past 12 months, ONC leads with a +36.5% total return vs TGTX's +23.5%. The 3-year compound annual growth rate (CAGR) favors TGTX at 9.1% vs ONC's 7.7% — a key indicator of consistent wealth creation.
| Metric | ONCBeOne Medicines L… | TGTXTG Therapeutics, … |
|---|---|---|
| YTD ReturnYear-to-date | +1.9% | +46.9% |
| 1-Year ReturnPast 12 months | +36.5% | +23.5% |
| 3-Year ReturnCumulative with dividends | +24.8% | +30.0% |
| 5-Year ReturnCumulative with dividends | +1.6% | +7.0% |
| 10-Year ReturnCumulative with dividends | +1045.6% | +436.5% |
| CAGR (3Y)Annualised 3-year return | +7.7% | +9.1% |
TGTX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ONC and TGTX each lead in 1 of 2 comparable metrics.
Risk & Volatility
ONC is the less volatile stock with a 0.70 beta — it tends to amplify market swings less than TGTX's 0.77 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TGTX currently trades 97.8% from its 52-week high vs ONC's 82.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ONCBeOne Medicines L… | TGTXTG Therapeutics, … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.70x | 0.77x |
| 52-Week HighHighest price in past year | $385.22 | $44.00 |
| 52-Week LowLowest price in past year | $218.31 | $25.28 |
| % of 52W HighCurrent price vs 52-week peak | +82.3% | +97.8% |
| RSI (14)Momentum oscillator 0–100 | 57.7 | 74.2 |
| Avg Volume (50D)Average daily shares traded | 237K | 2.1M |
Evenly matched — ONC and TGTX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ONC as "Buy" and TGTX as "Buy". Consensus price targets imply 26.6% upside for ONC (target: $401) vs -9.4% for TGTX (target: $39).
| Metric | ONCBeOne Medicines L… | TGTXTG Therapeutics, … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $401.29 | $39.00 |
| # AnalystsCovering analysts | 13 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.3% |
Insufficient data to determine a leader in this category.
Key Takeaway
TGTX leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). ONC leads in 1 (Valuation Metrics). 2 tied.
Best OverallTG Therapeutics, Inc. (TGTX)Leads 2 of 6 categories
Loading custom metrics...
ONC vs TGTX: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is ONC or TGTX a better buy right now?
For growth investors, TG Therapeutics, Inc.
(TGTX) is the stronger pick with 87. 3% revenue growth year-over-year, versus 40. 2% for BeOne Medicines Ltd. (ONC). BeOne Medicines Ltd. (ONC) offers the better valuation at 9. 6x trailing P/E (51. 9x forward), making it the more compelling value choice. Analysts rate BeOne Medicines Ltd. (ONC) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ONC or TGTX?
On trailing P/E, BeOne Medicines Ltd.
(ONC) is the cheapest at 9. 6x versus TG Therapeutics, Inc. at 15. 5x. On forward P/E, TG Therapeutics, Inc. is actually cheaper at 32. 3x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — ONC or TGTX?
Over the past 5 years, TG Therapeutics, Inc.
(TGTX) delivered a total return of +7. 0%, compared to +1. 6% for BeOne Medicines Ltd. (ONC). Over 10 years, the gap is even starker: ONC returned +1046% versus TGTX's +436. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ONC or TGTX?
By beta (market sensitivity over 5 years), BeOne Medicines Ltd.
(ONC) is the lower-risk stock at 0. 70β versus TG Therapeutics, Inc. 's 0. 77β — meaning TGTX is approximately 11% more volatile than ONC relative to the S&P 500. On balance sheet safety, TG Therapeutics, Inc. (TGTX) carries a lower debt/equity ratio of 40% versus 46% for BeOne Medicines Ltd. — giving it more financial flexibility in a downturn.
05Which is growing faster — ONC or TGTX?
By revenue growth (latest reported year), TG Therapeutics, Inc.
(TGTX) is pulling ahead at 87. 3% versus 40. 2% for BeOne Medicines Ltd. (ONC). On earnings-per-share growth, the picture is similar: TG Therapeutics, Inc. grew EPS 1747% year-over-year, compared to 637. 4% for BeOne Medicines Ltd.. Over a 3-year CAGR, TGTX leads at 504. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ONC or TGTX?
TG Therapeutics, Inc.
(TGTX) is the more profitable company, earning 72. 6% net margin versus 5. 4% for BeOne Medicines Ltd. — meaning it keeps 72. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TGTX leads at 20. 0% versus 8. 4% for ONC. At the gross margin level — before operating expenses — ONC leads at 87. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ONC or TGTX more undervalued right now?
On forward earnings alone, TG Therapeutics, Inc.
(TGTX) trades at 32. 3x forward P/E versus 51. 9x for BeOne Medicines Ltd. — 19. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ONC: 26. 6% to $401. 29.
08Which pays a better dividend — ONC or TGTX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is ONC or TGTX better for a retirement portfolio?
For long-horizon retirement investors, BeOne Medicines Ltd.
(ONC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 70), +1046% 10Y return). Both have compounded well over 10 years (ONC: +1046%, TGTX: +436. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ONC and TGTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(ONC: 35.5% · TGTX: 69.6%)Net Margin>
%
(ONC: 8.9% · TGTX: 66.0%)P/E Ratio<
x
(ONC: 9.6x · TGTX: 15.5x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.